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RNA-based therapeutic approaches show increasing promise, as exemplified by the recent progress in the development of ASOs and stopcodon RTCs as therapeutics for various genetic diseases 1, 2 . NMD is a quality-control process that degrades mRNAs with premature termination codons (PTCs) during translation 3 . mRNAs targeted by small molecules that allow the ribosome to read through stop codons are often subject to NMD, reducing the therapeutic potential of such RTCs 4 . NMD suppression has thus gained attention as a potential RNA-based therapy, but the approaches proposed so far have relied on general inhibition of the NMD machinery [5] [6] [7] . Transcript-specific, as opposed to global, inhibition of NMD is desirable, because in addition to protecting against the potential toxicity of truncated proteins, NMD has an important role in global post-transcriptional gene regulation-for example, when coupled with alternative splicing 8, 9 . Indeed, NMD has essential roles in developmental processes such as myogenesis, neurogenesis and lymphocyte maturation 1 . For example, UPF3B, a key regulator of NMD, is necessary for neural-progenitor cell differentiation and is mutated in various cognitive disorders 10 .
NMD relies on the presence of at least one exon-junction complex (EJC) bound to the mRNA downstream of a PTC. During translation, when a ribosome reaches a PTC, it associates with the release factors eRF1 and eRF3 and interacts with the downstream EJC through UPF1, UPF2, UPF3A and UPF3B 1 . This physical interaction provides a platform to recruit additional NMD factors, targeting the mRNA for destruction. Given that most EJCs are assembled 20-24 nucleotides upstream of each exon-exon junction during splicing and that the EJC is not required for splicing of most exons, we have developed an antisense approach that takes advantage of the predictable nature of EJC deposition 11 . antisense oligonucleotide-directed inhibition of nonsense-mediated mrna decay
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Nonsense-mediated mRNA decay (NMD) is a cellular qualitycontrol mechanism that is thought to exacerbate the phenotype of certain pathogenic nonsense mutations by preventing the expression of semi-functional proteins. NMD also limits the efficacy of read-through compound (RTC)-based therapies. Here, we report a gene-specific method of NMD inhibition using antisense oligonucleotides (ASOs) and combine this approach with an RTC to effectively restore the expression of full-length protein from a nonsense-mutant allele.
ASOs can be designed to block the binding sites of RNA-binding proteins, resulting in effects such as splicing modulation and inhibition of translation initiation, among others 12 . We tested whether ASOs can be used for targeted NMD inhibition by blocking EJC deposition on mRNA, downstream of a PTC. Although EJCs appear to be dispensable for most splicing events, they have roles in messenger ribonucleoprotein (mRNP) export from the nucleus and in translation 13 . Our approach should not affect such processes, because we target only the EJCs downstream of a PTC on a given mRNA, leaving the remaining upstream EJCs unaffected.
We first tested a well-characterized NMD substrate, full-length, threeexon HBB (encoding β-globin) with a CAG-to-TAG nonsense mutation in exon 2 (HBB-T39) (ref. 14) . We used Flp recombinase-mediated integration to stably express a single copy of this gene at a defined chromosomal location in U2OS T-REx cells. In this context, HBB-T39 mRNA expression was reduced to about 5% that of wild-type HBB ( Supplementary  Fig. 1 ). We designed a set of 2′-O-(2-methoxyethyl) (MOE) ribose-and phosphorothioate-modified 15-mer ASOs that together span the region of the HBB-T39 mRNA predicted to harbor an EJC and screened them individually for NMD-inhibiting activity ( Fig. 1a,b) . After transfection of the NMD reporter cells, many of the ASOs caused skipping of HBB exon 2; however, several ASOs resulted in minimal exon skipping and markedly increased the level of full-length spliced mRNA ( Fig. 1c and Supplementary Fig. 2) . We chose H-24 as the lead ASO and confirmed its dose-dependent activity, reflected in a threefold increase in HBB-T39 mRNA at the highest dose tested ( Fig. 1d) . Consistent with NMD inhibition, H-24 did not affect the levels of wild-type HBB mRNA ( Supplementary Fig. 3) .
To test the generality of our approach, we constructed a three-exon NMD minigene reporter based on the MECP2 gene encoding an S65X nonsense mutation (TCA to TGA) in the middle exon (exon 3 in the natural gene), similarly integrated at a defined location in U2OS T-REx cells. MECP2-S65X mRNA was efficiently degraded by NMD ( Supplementary Fig. 4 ). We screened a corresponding set of 19 ASOs spanning the presumptive EJC binding site near the 3′ end of this exon and identified multiple ASOs that increased the amount of full-length spliced mRNA ( Supplementary Fig. 5 ). One of several effective ASOs (M-33) for MECP2 resulted in a ~3-fold increase in mRNA ( Fig. 1e) . To verify the transcript-specific effect of NMD-inhibiting ASOs, we confirmed that the expression of several NMD-targeted endogenous mRNAs 15 was unchanged after ASO treatment ( Supplementary Fig. 6 ).
The above NMD substrates are simple three-exon genes or minigenes with a single predicted EJC downstream of a PTC. To test the broader applicability of our approach, we designed a pair of four-exon hybrid genes: one comprising HBB exons 1-3, with exon 3 and portions of the flanking introns from MECP2 inserted within HBB intron 2, and the other comprising MECP2 exons 2-4, with HBB exon 2 and portions of the flanking introns inserted within MECP2 intron 3 ( Fig. 1f and Online Methods). Using our optimal ASOs for these two genes (H-24 for HBB npg b r i e f c o m m u n i c at i o n s and M-33 for MECP2), we compared the effects of single and combined ASOs in inhibiting NMD of these target substrates with two presumptive downstream EJCs. In both cases, the combined treatment was more effective than either ASO alone ( Fig. 1g and Supplementary Fig. 7) .
NMD is sensitive to the cellular state and environment and can be inhibited by stresses such as hypoxia and amino-acid deprivation 16 . Furthermore, ASOs can have various off-target effects, although none has been linked to NMD efficiency 17 . To test the presumptive mechanism of action, we performed in vitro splicing of HBB pre-mRNA, followed by glutathione-S-transferase (GST)-mediated pull-down of eIF4A3, the anchor component of the EJC 18 , to confirm that an effective ASO blocks the interaction between the spliced mRNA and eIF4A3. Consistent with its predicted activity, H-24 ASO blocked the interaction between HBB mRNA and eIF4A3 in a dose-dependent manner ( Fig. 2a) .
To further establish the mechanism of action, we modified the HBB-T39 construct by adding 24 nucleotides at the 3′ end of exon 2. Owing to the position-specific nature of EJC binding, this modification shifts the predicted EJC-deposition site downstream of the sequence targeted by the H-24 ASO 1,18 (Fig. 2b) . The mRNA expressed from this construct (HBB-T39+24) was not affected by H-24, indicating that the ASO target sequence has to overlap with the predicted EJC-assembly site to inhibit NMD (Fig. 2c) .
Additionally, to rule out the possibility that the increase in steady-state mRNA level reflects an increased rate of transcription, we performed an actinomycin D chase assay to measure the mRNA decay rate. As expected, cells treated with H-24 ASO expressed HBB-T39 mRNA with greater stability (Supplementary Fig. 8 ). HBB-T39 mRNA has been reported to undergo biphasic decay, probably owing to rapid decay of the NMD-sensitive mRNA molecules occurring alongside slower decay of a subset of mRNA molecules that evade NMD 19 . Analysis of the half-lives in two phases revealed that the stability of HBB-T39 mRNA in ASO-treated cells was higher during the rapiddecay phase (estimated t 1/2 = 6.8 min for untreated versus 16.5 min for ASO-treated), whereas the decay rate during the slow phase remained unchanged (estimated t 1/2 > 12 h for both treatment groups).
To determine whether the target-mRNA increase results in an increase in the encoded protein after ASO treatment, we monitored the effect of ASO on protein synthesis via a GFP tag placed at the N terminus of HBB-T39. We observed a robust increase in the amount of truncated protein in response to ASO treatment ( Supplementary  Fig. 9 ). Notably, ASO treatment did not reduce the amount of fulllength protein expressed from the wild-type GFP fusion construct (Supplementary Fig. 10 ). We conclude that protein synthesis is not inhibited by an exon-targeting MOE phosphorothioate ASO, presumably because it is displaced from the mRNA upon passage of a translating ribosome.
RTCs are diverse classes of molecules that cause the ribosome to misrecognize a PTC and incorporate an amino acid, terminating at Supplementary Fig. 2) . (d) The optimal ASO for HBB (H-24, based on three experiments as in c) was tested at the indicated nominal concentrations (n = 3 independent transfections, *P < 0.05, **P < 0.001 versus no-ASO control, Student's t-test). (e) The same screening approach as in b was used to identify an ASO (M-33) that effectively inhibits NMD of MECP2 mRNA with a PTC in its penultimate exon (n = 3 independent transfections). See also Supplementary Figure 3 . the natural stop codon downstream and thereby restoring synthesis of full-length protein from mRNA with a nonsense mutation 20 . Although this is a promising strategy currently being tested in clinical trials, NMD diminishes the efficacy of read-through therapy by degrading the mRNAs targeted by such compounds 4, 5 .
To test the utility of our approach in improving the efficacy of RTCs, we designed a read-through reporter (HBB-T39(UGAC)), based on the GFP-tagged HBB-T39 construct described above, in which the TAG PTC and the following four nucleotides are replaced with TGACTAG. This stop codon and the downstream sequence weaken translation termination, allowing some spontaneous read-through and thereby increasing the sensitivity of detection of full-length HBB-GFP protein 21 . Translational read-through suppressed NMD to some extent, as was evident by the two-to three-fold increase in HBB-T39(UGAC) mRNA relative to HBB-T39 (Supplementary Fig. 1) . Nevertheless, we observed strong increases in both the truncated protein and the read-through product upon further NMD suppression by H-24 ASO treatment ( Fig. 2d and Supplementary Fig. 11) .
G418 is an aminoglycoside with read-through activity 4 . Co-treatment of U2OS cells expressing HBB-T39(UGAC) with H-24 ASO and G418 increased the full-length protein level by 6-fold, compared to a 2-fold increase with G418 alone and a 2.5-fold increase with H-24 ASO alone. Thus, antisense inhibition of NMD can augment the efficacy of an RTC. The ASO-induced increase in expression of truncated protein could be deleterious in some cases, but this would depend on the properties of the particular mutant protein and on the efficacy of the RTC.
The antisense approach we present here, which we call gene-specific antisense inhibition of NMD (GAIN), allows gene-specific inhibition of NMD without relying on skipping of a PTC-containing exon. This gene-specific feature, along with the clinically demonstrated efficacy and safety profiles of various ASO chemistries such as MOE phosphorothioate 2 , makes this a promising approach to inhibit NMD.
MeTHODS
Methods and any associated references are available in the online version of the paper. 
